Table 4. Main trends of clinical trials evaluating the effects of oxaliplatin as an off-label medication for cancer patients*.
| Location | Tumor type | Trials* | Phase | Notes |
|---|---|---|---|---|
|
Early clinical trials (phase I-II) | ||||
| Breast |
Breast cancer |
5 |
II |
In association with nucleoside analogs, docetaxel or trastuzumab. |
| Gastrointestinal system |
Biliary tract cancer |
9 |
II |
Often combined with nucleoside analogs, including 5-FU, capecitabine or gemcitabine. |
| Esophageal cancer |
19 |
I-II |
||
| Gastric cancer |
42 |
I-II |
||
| Pancreatic cancer |
14 |
I-II |
||
| Hematological tumors |
Lymphomas |
6 |
I-II |
Combined with nucleoside analogs and/or glucocorticoids. |
| Liver |
HCC |
6 |
I-II |
Often combined with nucleoside analogs. |
| Lung |
NSCLC |
3 |
II |
Combined with docetaxel or pemetrexed. |
| Reproductive tract |
Prostate cancer |
8 |
I-II |
Combined with nucleoside analogs or EGFR inhibitors. |
|
Advanced clinical trials(phase III-IV) | ||||
| Gastrointestinal system | Biliary tract cancer |
3 |
III |
Always combined with gemcitabine. |
| Gastric cancer |
4 |
III |
Combined with 5-FU or capecitabine. |
|
| Pancreatic cancer | 3 | III | Combined with 5-FU or gemcitabine. | |
Abbreviations: 5-FU, 5-fluorouracil; EGFR, epidermal growth factor receptor; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer. *started after January, 1st 2008 and not completed or terminated at the day of submission.